ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2012
Cost of care for colorectal cancer in Ireland: a health care payer perspective.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cost of illness in colorectal cancer: an international review.PharmacoEconomics · 2013Pooled it
- Quantifying the cost savings and health impacts of improving colonoscopy quality: an economic evaluation.BMJ quality & safety · 2025Article
- Analysis of the Direct Medical Costs of Colorectal Cancer in Antigua and Barbuda: A Prevalence-Based Cost-of-Illness Study.International journal of environmental research and public health · 2025Article
- CtDNA-guided de-escalation of adjuvant chemotherapy in stage III colon cancer: early model-based evaluation of cost-effectiveness.Therapeutic advances in medical oncology · 2025Article
- Article
- Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer.Therapeutic advances in medical oncology · 2024Article
- Protocol for Establishing a Stakeholder Group for Primary Care Research into Cancer Using a Modified 7P Framework and an e-Delphi Process.HRB open research · 2023Article
- Early detection of symptomatic cancer in primary care in Ireland: a protocol for a research prioritisation exercise.HRB open research · 2023Article
- Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Article
- Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients.Therapeutic advances in gastroenterology · 2021Article
- Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Article
- Model-based evaluation of the cost effectiveness of 3Therapeutic advances in gastroenterology · 2020Article
- A Correlation Study of the Colorectal Cancer Statistics and Economic Indicators in Selected Balkan Countries.Frontiers in public health · 2020Article
- Systems biology analysis identifies molecular determinants of chemotherapy-induced diarrhoea.Journal of molecular medicine (Berlin, Germany) · 2020Article
- Provider Costs of Treating Colorectal Cancer in Government Hospital of Malaysia.The Malaysian journal of medical sciences : MJMS · 2019Article
- Implementation of an optical diagnosis strategy saves costs and does not impair clinical outcomes of a fecal immunochemical test-based colorectal cancer screening program.Endoscopy international open · 2017Article
- Economic burden of colorectal cancer in Iran in 2012.Medical journal of the Islamic Republic of Iran · 2017Article
- The potential of imaging techniques as a screening tool for colorectal cancer: a cost-effectiveness analysis.The British journal of radiology · 2016Article
- Direct costs of radiotherapy for rectal cancer: a microcosting study.BMC health services research · 2015Article
- Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data.British journal of cancer · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveManagement options for colorectal cancer have expanded in recent years. We estimated average lifetime cost of care for colorectal cancer in Ireland in 2008, from the health care payer perspective.
methodA decision tree model was developed in Microsoft EXCEL. Site and stage-specific treatment pathways were constructed from guidelines and validated by expert clinical opinion. Health care resource use associated with diagnosis, treatment and follow-up were obtained from the National Cancer Registry Ireland (n=1,498 cancers diagnosed during 2004-2005) and three local hospital databases (n=155, 142 and 46 cases diagnosed in 2007). Unit costs for hospitalisation, procedures, laboratory tests and radiotherapy were derived from DRG costs, hospital finance departments, clinical opinion and literature review. Chemotherapy costs were estimated from local hospital protocols, pharmacy departments and clinical opinion. Uncertainty was explored using one-way and probabilistic sensitivity analysis.
resultsIn 2008, the average (stage weighted) lifetime cost of managing a case of colorectal cancer was €39,607. Average costs were 16% higher for rectal (€43,502) than colon cancer (€37,417). Stage I disease was the least costly (€23,688) and stage III most costly (€48,835). Diagnostic work-up and follow-up investigations accounted for 4 and 5% of total costs, respectively. Cost estimates were most sensitive to recurrence rates and prescribing of biological agents.
conclusionThis study demonstrates the value of using existing data from national and local databases in contributing to estimating the cost of managing cancer. The findings illustrate the impact of biological agents on costs of cancer care and the potential of strategies promoting earlier diagnosis to reduce health care resource utilisation and care costs.
Indexed as
Identifiers
21638069What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.